The initial step is to decide which particular lipid/lipoprotein abnormalities need to be evaluated and whether they need treatment. These disorders can be divided into elevations of plasma LDL, elevations of plasma @entity1674 , and decreases in plasma HDL. Frequently a @entity1 can have multiple lipid/lipoprotein abnormalities. The next step is to rule out secondary causes that could account for the abnormal lipid/lipoprotein levels. These secondary causes can be due to diet, various disease states, or drug therapy. One should be suspicious of a secondary cause if a @entity1 suddenly develops a lipid/lipoprotein abnormality or the lipid/lipoprotein profile suddenly worsens. Next one should consider the possibility of a @entity74 and therefore ask whether relatives have either premature @entity65 or @entity4977 . If the @entity412 levels are markedly elevated one should inquire about a family history of @entity788 . When the lipid/lipoprotein abnormality is markedly abnormal or begins at a young age, the likelihood of a @entity74 is increased and the family history assumes even greater importance. In most circumstances a routine lipid panel consisting of plasma @entity1674 , total @entity165 , HDL @entity165 , and calculated LDL and non-HDL @entity165 provides sufficient information to appropriately decide on who to treat and the best treatment approach. However, it should be recognized that there are certain special situations where more sophisticated and detailed laboratory studies can be helpful. The purpose of treating @entity4977 is to prevent the development of other diseases, particularly @entity65 . Thus the decision to treat should be based on the risk of the @entity407 leading to those medical problems. A number of guidelines have been published that discuss in detail cardiovascular risk assessment and provide recommendations on treatment strategies. Additionally, calculators are available on-line to determine an individual @entity1   s risk of developing @entity65 in the next 10 years or their lifetime risk. The first priority in treating @entity4977 is to lower the LDL @entity165 levels to goal, unless @entity1674 are markedly elevated. The second priority should be non-HDL @entity165 (non-HDL @entity165 = total @entity165     HDL @entity165 ), which is particularly important in @entity1 with elevated @entity412 levels (>200mg/dl). Whether increasing HDL levels or lowering @entity412 levels is beneficial in preventing @entity65 is uncertain. Lifestyle changes are the initial treatment but in most @entity1 drug therapy will be necessary.

Approach to the XXXX with Dyslipidemia

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity4977 :: ('MESH:D052439', 'Disease') :: ['lipid disorders'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic disorder'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1 :: (9606,Species) :: ['Patient']
